home / stock / shphf / shphf news
Summary Beijing YishengBio will merge with a SPAC vehicle, Summit Healthcare Acquisition, to list on the Nasdaq Exchange at a pre-money equity value of $834 million. Simcere Pharma of Nanjing announced a $507 million out-licensing to Spain’s Almirall for ex-China rights to ...
invoX Pharma, a Sino Biopharm subsidiary, will pay $161 million to acquire F-Star, a Cambridge, UK clinical-stage company developing bispecific drugs for immunotherapies. Xuanzhu Biopharm of Shandong out-licensed China rights for two anti-infectives to Shanghai SPH New Asia Pharma in ...
Vivo Capital, a US-China healthcare investor, held its first closing of a yuan-denominated private equity fund at $600 million, with a target of bringing the fund to $1.5 billion. SciNeuro Pharma, a Shanghai CNS company, acquired global rights to Lp-PLA2 inhibitors for neurodegenerati...